Hosted on MSN18h
MSD commences Phase III trial of DLBCL treatment
MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...
pharmaphorum23h
MSD starts pivotal trial of ROR1 drug in first-line lymphoma
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...